Drug
Avi 4658
Avi 4658: highest development phase Phase 2, developed by Sarepta Therapeutics, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sarepta Therapeutics, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| AVI-4658 (Eteplirsen) NCT01540409 | Phase 2 | Duchenne Muscular Dystrophy (DMD) |
| AVI-4658 (PMO) NCT00159250 | Phase 1/2 | Duchenne Muscular Dystrophy |
Latest
No recent events.
Follow Avi 4658 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.